Chhattisgarh Warns Against Overpriced Anti-Cancer Drugs After NPPA Price Cut

Illustration of a pharmacy medicine shelf with a price list, representing India capped anti-cancer drug prices for Chhattisgarh patients
Illustration: Praman News, generated graphic.

Last updated: November 18, 2026, 04:05 IST.

Chhattisgarh’s Food and Drug Administration has warned manufacturers, hospitals and retailers of action if 137 anti-cancer drugs are sold above their revised maximum retail prices. The warning follows an October 17 order by the National Pharmaceutical Pricing Authority capping trade margins on these drugs at 30 percent, with the new prices in effect since November 9.

The NPPA’s order used paragraph 19 of the Drugs (Prices Control) Order, 2013, to cap the trade margin, the gap between a drug’s price to the stockist or distributor and its maximum retail price, at 30 percent for non-scheduled formulations of the 137 specified anti-cancer molecules, including several patented drugs.

Manufacturers were told to calculate the new MRP using their March 2026 price to stockist or distributor, or the April 2025 to March 2026 average where no sales occurred that month. On October 28, the NPPA released a revised price list covering 543 brands, effective November 9, and said separately that the list of 137 covered drugs is not closed and will be updated periodically.

Under the order, manufacturers must submit their revised price details to both the NPPA and the concerned state drug controller within seven days of publication, which is the compliance step Chhattisgarh’s FDA is now following up on at the state level.

This is not the NPPA’s first attempt at reining in cancer drug prices. A similar 30 percent trade-margin cap imposed on 42 non-scheduled anti-cancer drugs in 2019 cut the MRP of 526 brands by as much as 90 percent, according to the government’s own account of that exercise, as reported by Upstox. Reports citing the NPPA say this round of 137 drugs could see MRPs fall by up to 70 percent once the new margin cap filters through.

What Chhattisgarh’s FDA is telling sellers to do

Chhattisgarh’s Food and Drug Administration Controller has directed manufacturers, distributors, stockists, retail sellers, hospitals, medical colleges and cancer treatment institutions in the state to display the revised or supplementary price list on their premises, and on their website where one exists. Patrika reported that the department also wants sellers to reconcile MRPs regularly and ensure supply is not disrupted while prices adjust.

Enforcement in the state runs through the Chhattisgarh Price Monitoring and Resource Unit (CGPMRU), which tracks compliance with central drug-pricing orders at the local level.

How a patient or family can check or report overcharging

Patients and caregivers in Chhattisgarh who suspect a pharmacy or hospital is charging above the revised MRP for any of the 137 drugs can call the CGPMRU helpline (9340597097) or the NPPA’s national helpline (1800-111-255), or write to cg-pmru@cg.gov.in or monitoring-nppa@gov.in, per the directive cited by Patrika. The NPPA also runs the Pharma Sahi Daam portal and app, where current ceiling prices for scheduled and capped drugs can be checked directly.

What’s next

The NPPA has said its list of covered anti-cancer drugs will be updated periodically, meaning more brands could see capped margins and lower MRPs in the coming months. Chhattisgarh’s enforcement push mirrors directives other states are expected to issue as the November 9 price revision takes hold nationally.

Frequently asked questions

Which drugs are covered by the price cap?
137 non-scheduled anti-cancer formulations named in the NPPA’s October 17, 2026 order, with the list open to future additions.

When did the new prices take effect?
November 9, 2026, per the NPPA’s revised MRP list released October 28.

Who should a patient contact in Chhattisgarh if a seller overcharges?
The Chhattisgarh Price Monitoring and Resource Unit at 9340597097 or cg-pmru@cg.gov.in, or the NPPA helpline at 1800-111-255.

Source: National Pharmaceutical Pricing Authority; Patrika.